Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anti-immunoglobulin E therapy for asthma.

Charles E Owen1

  • 1Novartis Horsham Research Centre, Horsham, UK

Pulmonary Pharmacology & Therapeutics
|October 31, 2002
PubMed
Summary

Reducing immunoglobulin E (IgE) levels with omalizumab offers a promising treatment for allergic asthma. This therapy effectively reduced asthma exacerbations and medication use, improving patients' quality of life.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Functional redundancy of class I phosphoinositide 3-kinase (PI3K) isoforms in signaling growth factor-mediated human neutrophil survival.

PloS one·2012
Same author

Immunoglobulin E: role in asthma and allergic disease: lessons from the clinic.

Pharmacology & therapeutics·2006
See all related articles

Area of Science:

  • Immunology
  • Allergy Research
  • Pulmonology

Background:

  • Immunoglobulin E (IgE) plays a key role in allergic asthma by triggering cellular events like mast cell degranulation.
  • Reducing IgE levels has shown potential in mitigating allergic inflammatory responses in asthma models.
  • IgE is a validated therapeutic target for allergic asthma management.

Purpose of the Study:

  • To evaluate the efficacy and safety of omalizumab, an anti-IgE antibody, in patients with moderate-to-severe allergic asthma.
  • To assess omalizumab's impact on asthma exacerbations, medication requirements, and quality of life.

Main Methods:

  • Clinical studies involving adults and children with moderate-to-severe allergic asthma.
  • Administration of omalizumab (anti-IgE antibody).
  • Evaluation of clinical outcomes including exacerbation frequency, medication use, and quality of life.

Main Results:

  • Omalizumab treatment was well-tolerated in patients.
  • Significant reduction in the frequency and number of asthma exacerbation episodes observed.
  • Lower usage of corticosteroids and other asthma control medications reported.
  • Improvements in patients' quality of life were noted.

Conclusions:

  • Omalizumab demonstrates clinical benefit and is a promising new treatment option for allergic asthma.
  • Targeting IgE with omalizumab effectively manages allergic asthma symptoms and reduces exacerbations.
  • The safety and efficacy profile supports omalizumab as a valuable therapeutic agent for allergic asthma.

Related Experiment Videos